RT Journal Article
SR Electronic
T1 The Thioredoxin-1 Inhibitor, PX-12, Suppresses Local Osteosarcoma Progression
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6013
OP 6021
DO 10.21873/anticanres.15420
VO 41
IS 12
A1 KINOSHITA, HIDEYUKI
A1 SHIMOZATO, OSAMU
A1 ISHII, TAKESHI
A1 KAMODA, HIROTO
A1 HAGIWARA, YOKO
A1 OHTORI, SEIJI
A1 YONEMOTO, TSUKASA
YR 2021
UL http://ar.iiarjournals.org/content/41/12/6013.abstract
AB Background/Aim: The thioredoxin-1 (Trx-1) inhibitor, PX-12, is active against several cancer types. This study aimed to evaluate its effects on local osteosarcoma (OS) progression and to describe PX-12-related signal transduction pathways. Materials and Methods: Publicly available expression cohort data were analyzed to determine the relationship between the expression levels of TXN, which codes for the Trx protein, and survival in patients with OS. Murine LM8 OS cells were stimulated with PX-12. Apoptosis-related protein levels, cell viability, caspase activity, and wound healing were evaluated. PX-12 efficacy in suppressing tumor progression was evaluated in C3H mice injected with LM8 cells. Results: High TXN expression was a negative prognostic factor for metastasis and overall survival in OS patients. PX-12 induced apoptosis in OS cells via the oxidative stress-MAPK-caspase 3 pathway and suppressed OS cell migration. PX-12 suppressed local OS progression. Conclusion: PX-12 is a potential therapeutic agent for use in suppressing local OS progression.